Amarin Receives Approval for VAZKEPA to Reduce Cardiovascular Risk

A round of applause for our research site physicians Dr Sam Henein and Dr Michael O’Mahony for their participation in the Amarin REDUCE-IT hypertriglyceridemia study! After more than a decade of development and testing, VAZKEPA becomes the first and only European Commission-approved treatment to reduce cardiovascular risk in high-risk, statin-treated adult patients who have elevated triglycerides and other risk characteristics as studied in REDUCE-IT. Keep up the amazing work guys

https://investor.amarincorp.com/news-releases/news-release-details/amarin-receives-european-commission-ec-approval-vazkepa-reduce